Edgewise Therapeutics, Inc.

NasdaqGS:EWTX Stok Raporu

Piyasa değeri: US$3.2b

Edgewise Therapeutics Yönetim

Yönetim kriter kontrolleri 4/4

Edgewise Therapeutics CEO'su Kevin Koch, Aug2017 tarihinde atandı, in görev süresi 7.25 yıldır. in toplam yıllık tazminatı $ 3.98M olup, şirket hissesi ve opsiyonları dahil olmak üzere 15% maaş ve 85% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.38% ine doğrudan sahiptir ve bu hisseler $ 12.01M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.2 yıl ve 4.8 yıldır.

Anahtar bilgiler

Kevin Koch

İcra Kurulu Başkanı

US$4.0m

Toplam tazminat

CEO maaş yüzdesi15.0%
CEO görev süresi7.3yrs
CEO sahipliği0.4%
Yönetim ortalama görev süresi4.2yrs
Yönetim Kurulu ortalama görev süresi4.8yrs

Son yönetim güncellemeleri

Recent updates

Edgewise: Stock Is Bouncing On Heart Disease Drug Data, Albeit From Just 7 Patients (Rating Upgrade)

Sep 19

We Think Edgewise Therapeutics (NASDAQ:EWTX) Can Afford To Drive Business Growth

Aug 12
We Think Edgewise Therapeutics (NASDAQ:EWTX) Can Afford To Drive Business Growth

Edgewise Therapeutics: Strong Open Label Data Makes For A Bullish Signal

Aug 05

Edgewise: Intriguing Drug Candidate, But Consider Selling After Recent Run

May 10

We're Not Very Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Rate

May 10
We're Not Very Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Rate

Edgewise Therapeutics: Behind The Massive Rally

Feb 18

Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth

Dec 07
Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth

Edgewise Therapeutics (NASDAQ:EWTX) Is In A Good Position To Deliver On Growth Plans

Aug 16
Edgewise Therapeutics (NASDAQ:EWTX) Is In A Good Position To Deliver On Growth Plans

Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth

Apr 28
Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth

We Think Edgewise Therapeutics (NASDAQ:EWTX) Can Afford To Drive Business Growth

Jan 13
We Think Edgewise Therapeutics (NASDAQ:EWTX) Can Afford To Drive Business Growth

Edgewise Therapeutics proposes $100M stock offering plan

Sep 13

Edgewise Therapeutics GAAP EPS of -$0.32 beats by $0.02

Aug 04

Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth

Aug 02
Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth

We're Hopeful That Edgewise Therapeutics (NASDAQ:EWTX) Will Use Its Cash Wisely

Mar 24
We're Hopeful That Edgewise Therapeutics (NASDAQ:EWTX) Will Use Its Cash Wisely

We're Hopeful That Edgewise Therapeutics (NASDAQ:EWTX) Will Use Its Cash Wisely

Nov 23
We're Hopeful That Edgewise Therapeutics (NASDAQ:EWTX) Will Use Its Cash Wisely

Edgewise Therapeutics names new chief medical officer

Apr 27

CEO Tazminat Analizi

Kevin Koch'un ücretlendirmesi Edgewise Therapeutics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

-US$116m

Mar 31 2024n/an/a

-US$106m

Dec 31 2023US$4mUS$595k

-US$100m

Sep 30 2023n/an/a

-US$89m

Jun 30 2023n/an/a

-US$81m

Mar 31 2023n/an/a

-US$76m

Dec 31 2022US$5mUS$572k

-US$68m

Sep 30 2022n/an/a

-US$61m

Jun 30 2022n/an/a

-US$56m

Mar 31 2022n/an/a

-US$51m

Dec 31 2021US$5mUS$525k

-US$43m

Sep 30 2021n/an/a

-US$36m

Jun 30 2021n/an/a

-US$27m

Mar 31 2021n/an/a

-US$21m

Dec 31 2020US$2mUS$425k

-US$17m

Dec 31 2019US$741kUS$425k

-US$10m

Tazminat ve Piyasa: Kevin 'nin toplam tazminatı ($USD 3.98M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 6.65M ).

Tazminat ve Kazançlar: Kevin 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.


CEO

Kevin Koch (64 yo)

7.3yrs

Görev süresi

US$3,975,855

Tazminat

Dr. Kevin Koch, Ph.D. is a Venture Partner at OrbiMed Advisors, LLC. He has been a Member of Scientific Advisory Board at OnKure, Inc. Dr. Koch serves as a Member of Scientific Advisory Board at Frontier M...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Peter Thompson
Co-Founder & Independent Chairman7.5yrsUS$226.00k0%
$ 0
Kevin Koch
President7.3yrsUS$3.98m0.38%
$ 12.0m
Badreddin Edris
Co-Founder & Independent Director7.5yrsUS$193.00k0.021%
$ 674.0k
Behrad Derakhshan
Chief Business Officer4.2yrsUS$1.76m0.016%
$ 514.3k
Joanne Donovan
Chief Medical Officer3.6yrsUS$1.72m0.015%
$ 494.2k
Alan Russell
Co-Founder7.4yrsUS$2.46m0.014%
$ 432.3k
R. Carruthers
Chief Financial Officer4.2yrsUS$772.02k0.082%
$ 2.6m
John Moore
General Counsel4.2yrsVeri yok0.0035%
$ 110.6k
Marc Semigran
Chief Development Officer1.9yrsVeri yokVeri yok

4.2yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim: EWTX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.2 yıldır).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Peter Thompson
Co-Founder & Independent Chairman7.5yrsUS$226.00k0%
$ 0
Kevin Koch
President7.4yrsUS$3.98m0.38%
$ 12.0m
Badreddin Edris
Co-Founder & Independent Director3.8yrsUS$193.00k0.021%
$ 674.0k
Alan Russell
Co-Founder7.3yrsUS$2.46m0.014%
$ 432.3k
Jonathan Root
Independent Director5.3yrsUS$199.50k0.017%
$ 531.2k
Laura Brege
Independent Director3.9yrsUS$208.00k0%
$ 0
Arlene Morris
Directorless than a yearVeri yokVeri yok
Barry Byrne
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Leslie Leinwand
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Jonathan Fox
Independent Director1.7yrsUS$485.00k0.012%
$ 369.2k
Lee Sweeney
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Craig McDonald
Member of the Scientific Advisory Board4.8yrsVeri yokVeri yok

4.8yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: EWTX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.8 yıldır).